Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Merck KGaA/Pfizer analysis of PD-L1 drug for rare skin cancer shows encouraging interim results
Merck KGaA/Pfizer analysis of PD-L1 drug for rare skin cancer shows encouraging interim results
Merck KGaA/Pfizer analysis of PD-L1 drug for rare skin cancer shows encouraging interim results
Submitted by
admin
on May 20, 2016 - 10:28am
Source:
BioPharma Dive
News Tags:
Merck KGaA
Pfizer
PD-L1
Merkel cell carcinoma
Headline:
Merck KGaA/Pfizer analysis of PD-L1 drug for rare skin cancer shows encouraging interim results
Do Not Allow Advertisers to Use My Personal information
